# Universitätsspital Zürich account plan

> Universitätsspital Zürich is the Canton of Zurich's university hospital, with CHF 1,880 million operating income in 2025 and 10,857 employees.

## At a glance

Universitätsspital Zürich (USZ) is an independent public-law institution owned by the Canton of Zurich, providing inpatient and outpatient care, university teaching and research with the University of Zurich, and public-interest services. In FY2025 it treated 42,317 inpatients and recorded 882,000 outpatient visits. Operating income rose 7.7% to CHF 1,880 million and the group posted a consolidated profit of CHF 36 million, its first since 2019, with an EBITDA margin of 6.6%. It had 10,857 employees (8,033.7 FTE) at 31 December 2025. The group also includes ZüriPharm AG, the USZ Foundation and a 40% stake in laundry company ZWZ AG; CEO is Monika Jänicke and the hospital board (Spitalrat) is chaired by André Zemp.

## Business units

- **USZ hospital** (about 94% of FY2025 consolidated operating income (TCHF 1,771,376)): The hospital itself, with inpatient revenue of TCHF 956,948 and outpatient revenue of TCHF 530,010 in 2025, plus laboratory orders and research and teaching paid by the University of Zurich. Segment profit was TCHF 33,012 after a loss in 2024. It is led by CEO Monika Jänicke and the Spitaldirektion, with medical director Malcolm Kohler as deputy CEO.
- **ZüriPharm AG**: The 100% subsidiary and former cantonal pharmacy in Schlieren, supplying drugs, patient-specific drug manufacturing and clinical-pharmaceutical advice, largely to the USZ. It made a profit of CHF 0.8 million in 2025, its second year under the USZ, and its manufacturing unit grew revenue by 5%.
- **USZ Foundation**: A consolidated foundation that promotes teaching, research, care and young talent at the USZ. It received donations of TCHF 17,016 in 2025, up from TCHF 6,977.
- **ZWZ AG (Zentralwäscherei Zürich, 40%)**: An equity-accounted laundry company providing linen services, co-owned with the City of Zurich and Kantonsspital Winterthur; profitable and dividend-paying.

## Strategic priorities

- **USZ 2030 strategy**: Four of six fields prioritised in 2025: highest quality, staff, digitalisation of the hospital and its processes, and self-financing, coordinated by a Transformation Office; it is now branded Spital der Zukunft.
- **Self-financing operations and new buildings**: The aim is to finance operations and the new buildings from its own resources over the long term, supported by a results-improvement programme in 2026.
- **Digital hospital**: An Epic clinical information system will replace 15 systems, with introduction starting in two years at the earliest; 166 small and seven large digital projects ran in 2025, including a real-time bed capacity dashboard, digital PROMs and automated rostering.
- **End-to-end patient pathways**: A lung tumour pathway since 1 February 2025, breast and gynaecological tumour pathways in 2025, and eight more pathways planned by end 2026.
- **Quality, compliance and culture**: A quality strategy adopted in June 2025 and a Compliance Roadmap with a CEO-chaired compliance committee, code of conduct, side-job register and a planned speak-up platform.
- **Staff retention**: A personnel strategy with five initiatives; staff turnover fell to 12.0%, and residents' clinical working time is being cut to 45 hours.

## Latest results

For H1 2026, the USZ reported a profit of CHF 15 million on revenue of CHF 890 million, with an EBITDA margin of 6.4%, against CHF 17 million and 6.8% in H1 2025 (unaudited figures for the USZ segment only). More than 22,000 inpatients were treated (+7%) and outpatient visits rose 5% to about 461,000. Management credits the higher patient numbers and strict cost and resource management. For 2026 the annual report expects the switch to TARDOC and outpatient flat rates to weigh on revenue.

## Investments and deals

- **MITTE1|2 new building**: A new campus building with 300 beds and 23 operating theatres, an emergency centre and modern radiology, with go-live targeted for summer 2031; TCHF 72,888 was invested in 2025, and the Kantonsrat approved a CHF 690 million commitment credit lent by the canton.
- **2025 capital spending**: Total investments of TCHF 151,211, including TCHF 107,858 in real estate, TCHF 19,295 in medical equipment and IT spending on data platforms and the migration from SAP R3 to SAP4Hana.
- **Further building programme**: Renovation of the listed WEST wing planned from 2028 and the laboratory centre NORD3 to follow MITTE1|2.
- **Radiopharmacy**: New leased space in Schlieren with a cyclotron, with production for medical use starting in early 2026.

## Challenges and risks

- **Outpatient tariffs**: Outpatient tariffs are still not cost-covering, and TARDOC and outpatient flat rates from 1 January 2026 are expected to have a negative revenue effect.
- **Cardiac surgery investigation**: The investigation commission UK 16/20 found glaring failures in 2016-2020 and reported 11 extraordinary deaths and 13 inappropriate uses of medical devices to the prosecutor; three Spitalrat members are stepping down.
- **Ageing, listed buildings**: Many listed buildings carry a significant renovation backlog while large construction projects must be refinanced.
- **Delayed clinical system**: The Epic clinical information system is delayed by a procurement appeal.
- **Cost pressure and skills shortages**: The CEO cites skills shortages, rising personnel and infrastructure costs, administrative burden and insufficient tariffs; personnel expense of CHF 1,058 million is the largest cost line.

## What leadership says

> "Wir investieren gezielt in Qualität, Spitzenmedizin und unsere Mitarbeitenden" — Monika Jänicke, CEO, H1 2026 results press release, 11 August 2026 (we invest in a targeted way in quality, top medicine and our staff)

> "Mit dem Neubau Campus Mitte 1|2 bauen wir das Spital der Zukunft." — Monika Jänicke, CEO, Interview with Heime und Spitäler, 1 August 2025 (with the new Campus Mitte 1|2 we are building the hospital of the future)

> "Was die Untersuchung aufgedeckt hat, ist ein Schock für uns alle." — Monika Jänicke, CEO, Press conference on the cardiac surgery investigation, 5 May 2026 (what the investigation uncovered is a shock to all of us)

> "Eine solide finanzielle Basis ist Voraussetzung dafür, dass das USZ seinen Auftrag in Versorgung, Forschung und Lehre langfristig erfüllen kann" — André Zemp, Chair of the Spitalrat, H1 2026 results press release, 11 August 2026


## Where a supplier can help

- **Clinical system migration support**: Replacing 15 systems with Epic, plus the SAP4Hana migration, creates demand for integration, data migration and change-management partners.
- **Hospital construction and equipment**: MITTE1|2, the WEST wing renovation and NORD3 open doors for medical equipment, building technology and facility suppliers.
- **Workforce tools**: Staff retention, automated rostering and reduced administration for residents, including dictation software, suit workforce management and clinical documentation vendors.
- **Cost and productivity programmes**: Self-financing, a results-improvement programme and outpatient tariff pressure make cost-saving and process-optimisation offers relevant.
- **Compliance and quality tooling**: The Compliance Roadmap, side-job register, speak-up platform and rebuilt clinical research audit programme fit governance, whistleblowing and quality management software.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Geschäftsbericht 2025 (Annual Report 2025, incl. consolidated financial statements)](https://www.usz.ch/app/uploads/2026/04/usz-geschaeftsbericht-2025.pdf)

Annual report · 2026-04-30

- Universitätsspital Zürich (USZ) is an independent public-law institution owned by the Canton of Zurich; its consolidated group adds ZüriPharm AG (100%, the former cantonal pharmacy), the USZ Foundation (consolidated) and a 40% equity stake in Zentralwäscherei Zürich ZWZ AG. Accounts follow Swiss GAAP FER and are audited by the cantonal Finanzkontrolle.
- FY2025 operating income rose 7.7% to CHF 1,880 million (2024: CHF 1,746 million) while operating expenses grew 3.0%; EBITDA margin improved from 2.9% to 6.6% and the group posted a consolidated profit of CHF 36 million (TCHF 35,876), its first since 2019, after a CHF 31 million loss in 2024.
- Activity: 42,317 inpatient discharges (+2.8%), 882,000 outpatient visits (+5.0%), case mix index 1.719, average length of stay 5.74 days; 19.1% of inpatients have supplementary (private/semi-private) insurance.
- Strategy «USZ 2030»: in 2025 management prioritised four of six fields (highest quality, staff, digitalisation, self-financing); a quality strategy and a personnel strategy were adopted; staff turnover fell to 12.0%.
- Digital: decision to replace 15 systems with an Epic clinical information system (KIS), rollout no earlier than in two years and delayed by a procurement appeal; 166 small and seven large digital projects in 2025, a real-time bed capacity dashboard, digital PROMs, automated rostering piloted with a USZ-wide rollout through 2026.
- Infrastructure: new building MITTE1|2 under construction with go-live (first patient) targeted for summer 2031; 2025 investments TCHF 151,211 in total, of which TCHF 107,858 in real estate (TCHF 72,888 for MITTE1|2); WEST wing renovation planned from 2028 and laboratory centre NORD3 next.
- Workforce: 10,857 employees and 8,033.7 FTE at 31 December 2025; personnel expense CHF 1,058 million, the largest cost line; 93 nationalities.
- Purchasing: a procurement cooperation with Kantonsspital Winterthur takes effect on 1 January 2027; about 400 cooperation contracts with other hospitals.
- Risks and outlook: outpatient tariffs still not cost-covering; the switch to TARDOC and outpatient flat rates on 1 January 2026 is expected to weigh on 2026 revenue; follow-up of the cardiac surgery investigation (UK 16/20) and compliance overhaul continue in 2026.

### [USZ erzielt erneut positives Halbjahresergebnis (H1 2026 results press release)](https://www.usz.ch/usz-erzielt-erneut-positives-halbjahresergebnis/)

Interim report · 2026-08-11

- USZ reported a profit of CHF 15 million in H1 2026 on revenue of CHF 890 million (unaudited half-year accounts of the USZ segment, without associated companies; the USZ publishes no audited half-year accounts).
- EBITDA margin 6.4%, versus CHF 17 million profit and 6.8% margin in H1 2025: a second consecutive positive half-year.
- Volumes: over 22,000 inpatients (+7% year on year) and about 461,000 outpatient visits (+5%).
- Management attributes the result to treating clearly more patients and continued strict management of costs and resources.
- CEO Monika Jänicke: the USZ invests in quality, top medicine and staff to finance operations and new buildings from its own resources in the long term.
- Chair André Zemp: a solid financial base is the precondition for fulfilling the mandate in care, research and teaching.
- The strategy is now branded «Spital der Zukunft» (hospital of the future).

### [Universitätsspital Zürich schliesst 2025 mit Gewinn ab (FY2025 results press release)](https://www.usz.ch/universitaetsspital-zuerich-schliesst-2025-mit-gewinn-ab/)

Report · 2026-03-13

- Press release of 13 March 2026 on FY2025 (figures before audit): consolidated profit CHF 36 million versus a CHF 31 million loss, the first profit since 2019.
- Operating income +7.7% to CHF 1,880 million, operating expenses +3.0%; EBITDA margin up from 2.9% to 6.6%; equity ratio 43.9%.
- Inpatient cases +2.8% to 42,317; outpatient visits +5.0% to 882,000; ZüriPharm AG profit CHF 0.8 million.
- Funding: in September 2025 the Kantonsrat approved a CHF 690 million commitment credit, lent by the canton, to finance the MITTE1|2 new building at cheaper terms.
- Compliance: a new Compliance Operating Model, a compliance committee in the Spitaldirektion, a speak-up programme and a code of conduct drafted with about 80 employees.
- Digital: 166 small and seven large projects in 2025, a central capacity dashboard, digital PROMs and automated rostering piloted.
- CEO Monika Jänicke: the profit creates room for quality, innovation and further development of the hospital.

### [«Mit dem Neubau Campus Mitte 1|2 bauen wir das Spital der Zukunft» (interview, Heime und Spitäler)](https://www.heimeundspitaeler.ch/management/mit-dem-neubau-campus-mitte-12-bauen-wir-das-spital-der-zukunft)

Executive talk · Monika Jänicke, CEO and Chair of the Spitaldirektion · 2025-08-01

- Interview of CEO Monika Jänicke with the trade magazine Heime und Spitäler (1 August 2025), two years into the job.
- Priorities under «USZ 2030»: excellence in medicine, research and training; digitalisation, process optimisation, staff retention, financial stabilisation and a better leadership culture.
- Digital: preparing the renewal of the clinical information system around the end-to-end patient pathway; real-time bed planning tool; automated rostering; AI used where data are secure and anonymised, e.g. in radiology.
- MITTE1|2 new building: 300 beds and 23 operating theatres, an emergency centre and modern radiology; she expects to make up the delay caused by a tender appeal.
- Canton-backed financing for the new building saves an expected CHF 51 million of interest over 2026-2040; CHF 52 million spent last year on renovating existing buildings, 40% of them listed.
- Goal to return to profit within the next years; three wishes to politics: fair, cost-covering tariffs, more room for strategic investment, support on digitalisation and skills shortages.
- Open to a structured international partnership like Swiss Medical Network's with Mayo Clinic, if on equal terms.

### [Medienkonferenz zu den Ergebnissen der Administrativuntersuchung Herzchirurgie (press conference presentation)](https://www.usz.ch/app/uploads/2026/05/MK-Praesentation_USZ.pdf)

Executive talk · Monika Jänicke, CEO; André Zemp, Chair of the Spitalrat · 2026-05-05

- Presentation of the 5 May 2026 press conference on the investigation commission UK 16/20 into the cardiac surgery clinic (2016-2020), with chair André Zemp, clinic director Omer Dzemali and CEO Monika Jänicke.
- The investigation found glaring failures by the then clinic leadership, Spitaldirektion and Spitalrat; the earlier claim that no patients were harmed was refuted.
- The Spitalrat apologised, set up information and counselling services and handed the findings to the Zurich public prosecutor, reporting 11 extraordinary deaths and 13 inappropriate uses of medical devices.
- The three Spitalrat members who served during the period under review are stepping down.
- Today: cardiac surgery mortality slightly below Swiss reference hospitals; ISO 9001 quality system; about 70% of procedures minimally invasive; Allianz Herzchirurgie Zürich-St. Gallen.
- Jänicke: USZ treats over 42,000 inpatients and almost 900,000 outpatients a year with about 11,000 staff; she commits to the realignment under Strategy 2030 and a deliberate culture change.
- Compliance Roadmap led by a CEO-chaired compliance committee: code of conduct, interest and transparency register (all side-job approvals expired 20 April), planned speak-up platform, rebuilt clinical research audit programme.

## Questions about Universitätsspital Zürich

### What is Universitätsspital Zürich?

USZ is the university hospital of the Canton of Zurich, an independent public-law institution providing patient care, teaching and research with the University of Zurich.

### What is USZ's revenue?

Operating income was CHF 1,880 million in 2025, with a consolidated profit of CHF 36 million. H1 2026 revenue was CHF 890 million.

### How many employees does USZ have?

USZ had 10,857 employees and 8,033.7 FTE at 31 December 2025.

### What is USZ's strategy?

USZ 2030, now branded Spital der Zukunft, prioritises highest quality, staff, a digital hospital and self-financing, including end-to-end patient pathways and a new clinical information system.

### Who leads USZ?

Monika Jänicke is CEO and chair of the Spitaldirektion, and André Zemp chairs the Spitalrat.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
